Bevacizumab in combination with capecitabine plus irinotecan as first-line therapy in metastatic colorectal cancer: A pooled analysis of 2 phase ii trials

Onkologie(Czech Republic)

Volumn 36, Issue 6, 2013, Pages 363-367

  García Alfonso, Pilar ^a   Muñoz Martin, Andrés ^a   Alvarez Suarez, Sonsoles ^a   Blanco Codeidido, Monserrat ^a   Mondejar Solis, Rebeca ^a   Tapia Rico, Gonzalo ^a   López Martín, Pilar ^a   Martin, Miguel ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Bevacizumab; Capecitabine; Irinotecan; Metastatic colorectal cancer; Pooled analysis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; IRINOTECAN;

ABSCESS; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BILE DUCT FISTULA; BLEEDING; BRONCHOSPASM; CANCER SURVIVAL; CAUSE OF DEATH; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC PAIN; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMORBIDITY; DEOXYCYTIDINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84879369025     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000351240     Document Type: Article

References (21)

1. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in oncology: Colon Cancer, v1, 2011. www.nccn.org/professionals/physician-gls/ pdf/colon.pdf.
2. Van Cutsem E, Nordlinger B, Cervantes A: ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010;21(suppl 5):v93-v97.
3. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007;370:135-142.
4. Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis Ch, Kouroussis Ch, Vamvakas L, Georgoulias V, Polyzos A: Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluoro-uracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). Br J Cancer 2012;106: 453-459.
5. Pectasides DG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papaxoinis G, Papakostas P, Bournakis E, Papandreou C, Fountzilas G: Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/ fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG). J Clin Oncol 2010;28:15s(suppl; abstr 3541).
6. Ducreux M, Adenis A, Pignon JP, François E, Chauffert B, Boucher E, Ychou M, Pierga JY, Montot-Grillot C, Conroy T: Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study). Eur J Cancer 2013;49:1236-1245.
7. Garcia-Alfonso P, Muñoz-Martin A, Mendez-Ureña M, Quiben-Pereira R, Gonzalez-Flores E, Perez-Manga G: Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer 2009;101: 1039-1043.
8. García-Alfonso P, Muñoz-Martin AJ, Alvarez-Suarez S, Jerez-Gilarranz Y, Riesco-Martinez M, Khosravi P, Martin M: Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. Br J Cancer 2010;103:1524-1528.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
11. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26: 2013-2019.
12. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; on behalf of the ML18147 Study Investigators: Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37.
13. Masi G, Loupakis F, Salvatore L, Cremolini C, Fornaro L, Schirripa M, Fea E, Granetto C, Antonuzzo L, Giommoni E, Allegrini G, Cupini S, Boni C, Banzi M, Chiara S, Sonaglio C, Valsuani C, Bonetti A, Boni L, Falcone A: A randomized phase III study evaluating the continuation of bevacizumab (bv) beyond progression in metastatic colorectal cancer (mCRC) patients (pts) who received BV as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 2012;23(suppl 9):ixe9(abstr LBA17).
14. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Car-reca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R: Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004;100:279-287.
15. Bollina R, Beretta G, Toniolo D, Cozzi C, Belloni P, Clerici M, Tralongo M: Capecitabine (C) and irinotecan (i) (CAPIRI): a good combination in elderly patients (pts) with advanced colorectal cancer (ACRC) as first line chemotherapy (CT): preliminary results of a phase II trial. Proc Am Soc Clin Oncol 2003;22:abstr 1332.
16. Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D, Roth AD: A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 2005;16:282-288.
17. Tewes M, Schleucher N, Achterrath W, Wilke HJ, Frings S, Seeber S, Harstrick A, Rustum YM, Vanhoefer U: Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. Ann Oncol 2003;14:1442-1448.
18. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779-4786.
19. Köhne C-H, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, Braumann D, Joosens E, Müller L, Janssens J, Bokemeyer C, Reimer P, Link H, Späth-Schwalbe E, Wilke HJ, Bleiberg H, Van Den Brande J, Debois M, Bethe U, Van Cutsem E: Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008;19:920-926.
20. Reinacher-Schick AC, Kubicka S, Freier W, Arnold D, Dietrich G, Geissler M, Hegewisch-Becker S, Graeven U, Schmoll H, Schmiegel W: Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or cape-citabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): a randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J Clin Oncol 2008;26:15s(suppl; abstr 4030).
21. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V: Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104-a randomized trial of the German AIO CRC study group. J Clin Oncol 2011;29:1050-1058.